Phase 1 studies of GD2-specific CAR-T cells for neuroblastoma, CAR-T cells specifically targeting HER2, EGFR and IL-13 for glioblastoma multiforme, mesothelin-specific CAR-T cells for advanced malignant pleural mesothelioma or pancreatic cancer, CAR-T cells specific for epidermal growth factor receptor (EGFR) for advanced nonsmall-cell lung cancer and cholangiocarcinoma, CEA specific CAR-T cells for metastatic CRC have reported positive initial results [92–99]. This evidence concerns the gene EGFR and lung cancer.